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The International Agency for Research on
Cancer (IARC) has classiﬁed arsenic in drink-
ing water as a group 1 carcinogen that causes
skin cancer, bladder cancer, and lung cancer
(IARC 2002). Substantial evidence supports
the biologic plausibility that exposure to
arsenic can lead to skin and bladder cancer.
For example, arsenic concentrates in the skin
and is known to cause nonmalignant skin
lesions [National Research Council (NRC)
2001], and the major pathway of excretion is
in urine, giving plausibility to increased blad-
der cancer rates (NRC 2001). Although it is
known that inhalation of arsenic may cause
lung cancer, the findings of increased lung
cancer mortality after ingestion in drinking
water were unexpected because all other
known lung carcinogens act via inhalation.
However, the evidence based on multiple
studies in Taiwan (Chen and Wang 1990;
Chen et al. 1985, 1988; Wu et al. 1989),
Chile (Ferreccio et al. 2000; Smith et al.
1998), Argentina (Hopenhayn-Rich et al.
1998), and Japan (Tsuda et al. 1989, 1995) is
sufﬁcient to conclude that there is a causal rela-
tionship. In fact, lung cancer is the main long-
term cause of death from ingesting arsenic in
drinking water (NRC 2001). In region II of
Chile, which includes the city of Antofagasta,
overall lung cancer mortality rates for men and
women were previously found to be at least
3-fold higher than for the rest of Chile (Smith
et al. 1998), and lung cancer relative risk
estimates increased nearly 9-fold in those with
the highest exposures (Ferreccio et al. 2000).
Several known lung carcinogens cause
chronic nonmalignant respiratory diseases,
including cigarette smoking, which causes
chronic obstructive pulmonary disease
(COPD); asbestos, which causes asbestosis;
and silica, which causes silicosis. To date,
however, relatively little attention has been
given to whether or not ingestion of arsenic in
drinking water causes nonmalignant pul-
monary disease. The first reports of chronic
respiratory symptoms came from small inves-
tigations in Antofagasta in the 1970s (Zaldivar
1974, 1977, 1980; Zaldivar and Ghai 1980).
Before 1958, the water supply in the main city
of Antofagasta had an arsenic concentration of
about 90 µg/L. A growing population led to
supplementation of Antofagasta’s water supply
in the late 1950s with water from rivers with
arsenic concentrations near 1,000 µg/L.
Because this area is among the driest places on
Earth, there are very few individual water sup-
plies, and almost everyone drinks water from
the same municipal sources. After the installa-
tion of a new treatment plant in 1971, arsenic
levels in Antofagasta water dropped abruptly
to about 90 µg/L and have been progressively
reduced further in recent years (Ferreccio et al.
2000). These data are shown in Figure 1.
In a 1998 publication concerning region
II, increased COPD mortality was reported
for the 30- to 39-year age group (Smith et al.
1998). Based on the time period in which
mortality was assessed (1989–1993), subjects
in the 30- to 39-year age group would have
been in utero or young children at the time of
the peak exposure period in Antofagasta.
These results were based on a small number of
cases but were later supported by findings
from other arsenic-exposed regions. For exam-
ple, increases in symptoms of chronic respira-
tory disease were found to be associated with
arsenic ingestion in studies in West Bengal,
India (De et al. 2004; Guha Mazumder et al.
2000) and Bangladesh (Milton and Rahman
2002). Recently, two studies in West Bengal
involving participants with arsenic-caused skin
lesions reported major deﬁcits in pulmonary
function (von Ehrenstein et al. 2005) and a
10-fold increase in prevalence of bronchiec-
tasis identified by high-resolution computed
tomography (Guha Mazumder et al. 2005).
The distinct period of high arsenic expo-
sure in Antofagasta from 1958 through 1970
offers the opportunity to investigate the health
effects of early-life arsenic exposure. In this
study, we take advantage of this unique situa-
tion in order to assess adult mortality in those
born during the high-exposure period who
would have experienced exposure in utero as
well as early childhood, and those born just
before 1958 who would have experienced high
exposure during childhood but not in utero.
Materials and Methods
We obtained computerized mortality data for
1989–2000 from the Ministry of Health for all
13 regions of Chile. Deaths were divided into
two groups: those who were residents of
Antofagasta and neighboring Mejillones, cities
that have the same water source; and those
who were residents in all regions of Chile other
than region II, in which Antofagasta and
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Arsenic in drinking water is an established cause of lung cancer, and preliminary evidence suggests that
ingested arsenic may also cause nonmalignant lung disease. Antofagasta is the second largest city in
Chile and had a distinct period of very high arsenic exposure that began in 1958 and lasted until 1971,
when an arsenic removal plant was installed. This unique exposure scenario provides a rare opportunity
to investigate the long-term mortality impact of early-life arsenic exposure. In this study, we compared
mortality rates in Antofagasta in the period 1989–2000 with those of the rest of Chile, focusing on sub-
jects who were born during or just before the peak exposure period and who were 30–49 years of age at
the time of death. For the birth cohort born just before the high-exposure period (1950–1957) and
exposed in early childhood, the standardized mortality ratio (SMR) for lung cancer was 7.0 [95% conﬁ-
dence interval (CI), 5.4–8.9; p < 0.001] and the SMR for bronchiectasis was 12.4 (95% CI, 3.3–31.7;
p < 0.001). For those born during the high-exposure period (1958–1970) with probable exposure
in utero and early childhood, the corresponding SMRs were 6.1 (95% CI, 3.5–9.9; p < 0.001) for lung
cancer and 46.2 (95% CI, 21.1–87.7; p < 0.001) for bronchiectasis. These ﬁndings suggest that expo-
sure to arsenic in drinking water during early childhood or in utero has pronounced pulmonary effects,
greatly increasing subsequent mortality in young adults from both malignant and nonmalignant lung
disease. Key words: arsenic, bronchiectasis, childhood exposure, chronic obstructive pulmonary disease,
drinking water, in utero exposure. Environ Health Perspect 114:1293–1296 (2006).
doi:10.1289/ehp.8832 available via http://dx.doi.org/ [Online 27 March 2006]Mejillones are located. Two birth cohorts were
defined for this investigation: those born in
the period 1958–1970 (probable in utero
exposure if resident in Antofagasta/Mejillones)
and those born in 1950–1957 (probable child-
hood exposure if born in Antofagasta/
Mejillones). Causes of death were coded
according to the International Classiﬁcation of
Diseases, 9th Revision (ICD-9; World Health
Organization 1978), including lung cancer
(ICD-9 code 162) and chronic respiratory dis-
ease (ICD-9 codes 490, 491, 492, 494, and
496). We obtained annual estimates of the
population living in Antofagasta/Mejillones in
region II, and for the rest of Chile excluding
region II, for 1989–2000 from the National
Institute of Statistics (Instituto Nacional de
Estadísticas) stratiﬁed by age and sex.
In 2000, the most recent year for which
mortality data are available, the oldest persons
in the first birth cohort born in the period
1950–1957 would have been 50 years old. We
therefore calculated standardized mortality
ratios (SMRs) for men and women separately,
30–49 years of age, using 10-year age groups
(30–39 and 40–49 years) for standardization.
Mortality in younger ages was not included
because death from lung cancer or chronic res-
piratory disease is extremely rare in individuals
< 30 years of age. We calculated SMRs as the
observed number of deaths divided by the
expected number of deaths, using all regions in
Chile outside of region II as the referent popu-
lation. We estimated SMRs for lung cancer, for
bronchiectasis, and for other COPD causes of
death excluding bronchiectasis, and also for all
other causes of death excluding lung cancer and
COPD. We calculated tests of signiﬁcance and
confidence intervals (95% CIs) based on the
Poisson distribution (Selvin 1995). In view of
the clear direction of the a priori hypotheses for
arsenic and both malignant and nonmalignant
pulmonary diseases, we conducted one-tailed
tests of signiﬁcance for increases in these out-
comes. We assessed tests for effect modiﬁcation
by age group (comparing 30–39 and 40–49
year age groups) and tests for effect modiﬁca-
tion by sex and for differences between those
born in 1950–1957 and 1958–1970 by testing
the pertinent Poisson regression interaction
terms with two-tailed tests.
Results
SMRs for lung cancer and COPD are given in
Table 1 for the 30–39 and 40–49 age groups
separately and combined and for men and
women separately and combined. Based on the
Poisson regression interaction terms, there was
no evidence of differences in rate ratios between
30–39 and 40–49 age groups for lung cancer
and COPD causes of death, so we focused on
the SMRs for the overall age range 30–49 years.
For lung cancer, the SMR for 30–49 years of
age was increased for those born in the period
1950–1957 for both men (SMR = 8.2; 95%
CI, 6.2–10.8, p < 0.001) and women (SMR =
4.7; 95% CI, 2.7–7.7; p < 0.001). The lung
cancer SMR was also increased for those born
in 1958–1970 (women: SMR = 2.9; 95% CI,
0.6–8.5; p = 0.087; men: SMR = 8.1; 95% CI,
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Table 1. SMRs for bronchiectasis, other COPD, all other deaths, and lung cancer for Antofagasta/Mejillones, for ages 30–49, for men and women both separately
and pooled.
Born 1950–1957 Born 1958–1970
Age (years) Sex Cause of death O E SMR (95% CI) p-Value O E SMR (95% CI) p-Value
30–39 Male Lung cancer 15 1.17 12.8 (7.1–21.1) < 0.001 12 1.30 9.2 (4.8–16.1) < 0.001
Bronchiectasis 3 0.15 19.4 (4.0–56.8) 0.001 2 0.05 36.4 (4.1–132) 0.001
Other COPD 1 0.21 4.7 (0.1–26.0) 0.193 1 0.46 2.2 (0.1–12.1) 0.368
All other deaths 129  155.78 0.8 (0.7–1.0) 0.987 305 304.41 1.0 (0.9–1.1) 0.494
30–39 Female Lung cancer 2 0.48 4.2 (0.5–15.1) 0.084 3 0.83 3.6 (0.7–10.5) 0.052
Bronchiectasis 0 0.04 0 — 6 0.14 42.9 (15.7–93.4)  < 0.001
Other COPD 2 0.14 13.9 (1.7–50.2) 0.009 4 0.33 12.2 (3.3–31.2) < 0.001
All other deaths 74  64.95 1.1 (0.9–1.4) 0.145 145 113.73 1.3 (1.1–1.5) 0.003
30–39 Pooled Lung cancer 17 1.65 10.3 (6.0–16.5) < 0.001 15 2.14 7.0 (3.9–11.6) < 0.001
Bronchiectasis 3 0.19 15.8 (3.2–46.0) 0.001 8 0.19 41.1 (17.7–80.9)  < 0.001
Other COPD 3 0.36 8.4 (1.7–24.5) 0.006 5 0.79 6.3 (2.1–14.8) 0.001
All other deaths 203  220.73 0.9 (0.8–1.1) 0.891 450 418.14 1.1 (1.0–1.2) 0.064
40–49 Male Lung cancer 37 5.14 7.2 (5.1–9.9) < 0.001 1 0.29 3.4 (0.01–18.9)  0.255
Bronchiectasis 0 0.10 0 — 0 0 0 —
Other COPD 3 1.30 2.3 (0.5–6.7) 0.144 1 0.10 10.2 (0.3–56.8) 0.093
All other deaths 270  292.37 0.9 (0.8–1.0) 0.911 21 19.66 1.1 (0.7–1.6) 0.411
40–49 Female Lung cancer 14 2.90 4.8 (2.6–8.1) < 0.001 0 0.20 0.0 —
Bronchiectasis 1 0.04 27.6 (0.7–154)  0.036 1 0.0 0.0 —
Other COPD 2 0.76 2.6 (0.3–9.5) 0.177 1 0.04 27.4 (0.7–153)  0.036
All other deaths 178  147.78 1.2 (1.0–1.4) 0.009 17 11.92 1.4 (0.8–2.3) 0.097
40–49 Pooled Lung cancer 51 8.04 6.3 (4.7–8.3) < 0.001 1 0.50 2.0 (0.01–11.2)  0.391
Bronchiectasis 1 0.13 7.5 (0.2–42.0) 0.124 1 0.0 0.0 —
Other COPD 5 2.06 2.4 (0.8–5.7) 0.059 2 0.13 14.9 (1.8–53.7) 0.008
All other deaths 448  440.15 1.0 (0.9–1.1) 0.361 38 31.58 1.2 (0.9–1.7) 0.146
30–49 Male Lung cancer 52 6.31 8.2 (6.2–10.8) < 0.001 13 1.60 8.1 (4.3–13.9) < 0.001
Bronchiectasis 3 0.25 12.0 (2.4–34.9) 0.002 2 0.05 36.4 (4.1–132)  0.001
Other COPD 4 1.52 2.6 (0.7–6.7) 0.068 2 0.56 3.6 (0.4–12.9) 0.108
All other deaths 399  448.15 0.9 (0.8–1.0) 0.991 326 324.07 1.0 (0.9–1.1) 0.465
30–49 Female Lung cancer 16 3.38 4.7 (2.7–7.7) < 0.001 3 1.03 2.9 (0.6–8.5) 0.087
Bronchiectasis 1 0.07 13.9 (0.2–77.1) 0.070 7 0.14 50.1 (20.0–103)  < 0.001
Other COPD 4 0.90 4.4 (1.2–11.3) 0.014 5 0.37 13.7 (4.4–32) < 0.001
All other deaths 252  212.73 1.2 (1.0–1.3) 0.005 162 125.64 1.3 (1.1–1.5) 0.001
30–49 Pooled Lung cancer 68 9.69 7.0 (5.4–8.9) < 0.001 16 2.63 6.1 (3.5–9.9) < 0.001
Bronchiectasis 4 0.32 12.4 (3.3–31.7) < 0.001 9 0.19 46.2 (21.1–87.7)  < 0.001
Other COPD 8 2.42 3.3 (1.4–6.5) 0.004 7 0.92 7.6 (3–15.6) < 0.001
All other deaths 651 660.88 1.0 (0.9–1.1) 0.655 488 449.71 1.1 (1.0–1.2) 0.039
Abbreviations: E, expected; O, observed.
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Figure 1. Arsenic concentrations in Antofagasta/
Mejillones water by year. An arsenic removal plant
was installed in 1971.4.3–13.9; p < 0.001). Concerning COPD
mortality, bronchiectasis SMRs were markedly
increased for both men and women, especially
for those born in the high-exposure period
1958–1970 (women: SMR = 50.1; 95% CI,
20.0–103; p < 0.001; men: SMR = 36.4; 95%
CI, 4.1–132; p = 0.001). SMRs for other
COPD causes of death excluding bronchiecta-
sis were elevated, but much less than for
bronchiectasis. Finally, for all other causes of
death combined, there was little evidence of
increased mortality for either birth cohort, as
shown in Table 1.
The lung cancer relative risks are higher for
men than for women, but the CIs for women
are wide because of the relatively small num-
bers and overlap the lung cancer SMR for men
(point estimate for men 30–49 years of age,
8.1; 95% CI for women, 0.6–8.5; Table 1).
Testing Poisson regression interaction terms,
there was little evidence of effect modiﬁcation
by sex for the period 1950–1957 (p = 0.23),
but testing for effect modification for those
born in the period 1958–1970 yields a p-value
of 0.04, with higher relative risks for men than
for women (8.1 for men and 2.9 for women).
The pooled results are presented in Table 1
and Figure 2. They show that lung cancer rates
are greatly increased for both those born in
1950–1957 with childhood exposure and for
those born in 1958–1970 who would have
experienced in utero exposure. However, for
bronchiectasis, and to a lesser extent for other
COPD mortality, the SMRs are much higher
for those born in 1958–1970 (SMR = 46.2;
95% CI, 21.1–87.7; p < 0.001) than for those
born in 1950–1957 before the very high expo-
sures started (SMR = 12.4; 95% CI, 3.3–31.7;
p < 0.001; Poisson regression test for difference
in bronchiectasis rate ratios for the two periods,
p = 0.02).
Discussion
Region II of Chile provides a unique opportu-
nity to investigate arsenic health effects. It is
one of the driest areas of the world, and water
used in major cities and towns comes from sin-
gle sources with known arsenic concentration.
Furthermore, there was an abrupt onset of high
exposure in 1958 in Antofagasta, the major city
of region II with a population at that time of
about 200,000 (Zaldivar 1974), and an abrupt
reduction in exposure in 1971 when the ﬁrst
large arsenic removal plant in the world was
installed there. Such clear-cut exposure patterns
are rare in environmental epidemiology, except
perhaps radiation exposure from use of the
atomic bomb in Hiroshima and Nagasaki and,
to a lesser extent, ionizing radiation from
accidents at nuclear reactors.
The magnitude of the effects found on lung
cancer and bronchiectasis mortality has no
parallel with effects of other environmental
exposures occurring in utero and/or in early
childhood. No lung cancer cases were reported
in 40 years among the in utero–exposed sur-
vivors of the atomic bombing of Hiroshima
and Nagasaki (Yoshimoto et al. 1988).
Children with the highest gamma radiation
exposure in Hiroshima and Nagasaki < 10 years
of age did not experience increased lung cancer
risks as adults, but those exposed in the age
range of 10–19 years had lung cancer relative
risk estimates of about 2.5 those of young
adults 30–39 years of age (Shimizu et al. 1990,
ﬁgure 2). The evidence for an effect of child-
hood exposure to environmental tobacco
smoke on adult lung cancer rates is mixed, with
a meta-analysis ﬁnding no overall evidence of
increased risks (Boffetta et al. 2000). However,
a prospective study reported a relative risk esti-
mate of 3.6 (95% CI, 1.2–11.1) based on four
lung cancer cases among those with “many
hours” of daily exposure (Vineis et al. 2005). By
contrast, we report here a total of 84 deaths
from lung cancer after childhood exposure to
high concentrations of arsenic in drinking water
in Chile, a 6- and 7-fold increase above rates in
the rest of Chile (Table 1).
Some supportive evidence provides bio-
logic plausibility for arsenic having effects
in utero. Arsenic crosses the placenta in ani-
mals and humans, and there is human evi-
dence that arsenic is a developmental toxicant
affecting birth weight and reproductive out-
comes (Concha et al. 1998; Hanlon and Ferm
1987; Hopenhayn et al. 2003; Hopenhayn-
Rich et al. 1999, 2000). A study conducted
in Bangladesh showed an increased risk for
stillbirth [odds ratio (OR) = 2.5; 95% CI,
1.5–4.9] and spontaneous abortion (OR =
2.5; 95% CI, 1.5–4.3) in women with current
arsenic exposure ≥ 100 µg/L in water (Milton
et al. 2005), and a study in West Bengal found
increased risks of stillbirths (OR = 6.1; 95%
CI, 1.5–24.0) (von Ehrenstein et al. 2006). As
a whole, these epidemiologic data provide evi-
dence that arsenic exposure in utero could be
associated with a number of adverse effects.
The present study, however, is the ﬁrst to pro-
vide evidence that early-life exposures may
produce effects manifesting in adults.
Oral-dose animal studies demonstrate
arsenic teratogenicity (Chattopadhyay et al.
2002; Vahter 1994). Of particular relevance to
our study is evidence that arsenic is a transpla-
cental carcinogen in mice (Waalkes et al.
2000). Female offspring of pregnant mice that
were given high doses of arsenic in their drink-
ing water developed tumors at multiple sites,
including the lung, with lung carcinoma
increased to 5 of 24 (21%) compared with 0 of
25 (0%) in the unexposed controls.
Strengths of our study include the exten-
sive documentation of arsenic in drinking
water in the Antofagasta water system.
Records of arsenic levels in Antofagasta have
been kept for the last 50 years, and almost all
residents drink from the same water supply.
One potential limitation of this study is that it
is ecologic in nature, because overall mortality
rates in the cities of Antofagasta/Mejillones
were compared with those of the rest of Chile.
Residence was determined from death certiﬁ-
cates and relates to residence at the time at
death. We cannot be certain that those mani-
festing the increased mortality were actually
born in Antofagasta/Mejillones. However, the
increases in relative risks are far too great to
result from bias due to in-migration of very
high-risk persons born elsewhere. We con-
clude that the effects are most probably due to
arsenic in the water and that, if anything, they
are diluted by in-migration of people who
were born and grew up elsewhere in Chile.
The study’s weakness lies in its reliance on
death certiﬁcates, even though Chilean mortal-
ity records are well documented: Laws require
that deaths be registered with the Civilian
Registration Service (Servicio de Registro
Civil), whereas another branch of government,
the National Institute of Statistics (Instituto
Nacional de Estadísticas), oversees validation of
the generated data. Death certiﬁcates are coded
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Table 2. Smoking habits among men and women in the two major cities in region II in 1990 compared with data for the rest of Chile [no. (%)].
Smoking habits (cigarettes/day)
Nonsmokers Occasional 1–9 10–19 ≥ 20 Unknown Total
Antofagasta 163,500 (76.4) 13,223 (6.2) 27,445 (12.8) 7,845 (3.7) 1,800 (0.8) 270 (0.1) 214,083 (100)
Calama 92,214 (80.4) 8,268 (7.2) 10,944 (9.5) 1,788 (1.6) 1,233 (1.1) 222 (0.2) 114,669 (100)
Rest of Chile 5,443,466 (75.1) 581,686 (8.0) 837,878 (11.6) 228,617 (3.2) 109,421 (1.5) 46,215 (0.6) 7,247,283 (100)
Data were obtained from the Ministerio de Planiﬁcación y Coordinación Nacional Republica de Chile IIIa, Encuesta Caracterización Socio Económica Nacional (1992).
Disease type
S
M
R
50
40
30
20
10
0
Bronchiectasis Other COPD Lung cancer All other deaths
Born 1950–1957
Born 1958–1970
Rest of Chile
Figure 2. COPD SMRs for Antofagasta/Mejillones
for individuals 30–49 years of age, pooled.Smith et al.
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according to the standard ICD, and the 1996
World Health Statistics cited Chile as having
100, 100, and 98% of all estimated deaths reg-
istered for the years 1991, 1993, and 1994,
respectively (World Health Organization
1998). However, although death certificates
provide reasonably good data for lung cancer
studies, they have known limitations for identi-
fying death from chronic respiratory disease
(Selikoff and Seidman 1992). This leads one to
question whether medical practices in region II
might have led to overdiagnosis of chronic res-
piratory disease as a cause of death placed on
death certificates, particularly deaths from
bronchiectasis. However, separating out the
ﬁndings concerning bronchiectasis from other
COPD causes of death was conducted with a
clear a priori hypothesis. Although previous
mention had been made in the literature of
bronchiectasis and arsenic, it was the recent
ﬁnding of a 10-fold increase in bronchiectasis
prevalence in persons with high exposure to
arsenic and arsenic-caused skin lesions in West
Bengal, India (Guha Mazumder et al. 2005),
that led us speciﬁcally to evaluate bronchiectasis
in this study.
Although smoking is strongly associated
with mortality from lung cancer and COPD,
confounding due to smoking is unlikely.
Smoking is not a strong risk factor for bronchi-
ectasis and so would not confound our ﬁndings
regarding this disease (Barker 2002). And even
in extreme form, confounding could not pro-
duce the marked elevation of lung cancer rela-
tive risks we have found (Axelson 1980). In
addition, smoking data do not indicate higher
smoking rates in region II than in the rest of
Chile, according to a national survey con-
ducted in 1990 (Ministerio de Planiﬁcación y
Cooperación Nacional Republica de Chile
1992). The survey included the two largest
cities in region II (Antofagasta and Calama),
which constitute 80% of the region II popula-
tion; the proportion of smokers in these two
cities was found to be lower than the rest of
Chile, and the two cities also had a smaller pro-
portion of people who smoked more than one
pack per day (Table 2) (Smith et al. 1998).
Although there is some evidence that exposure
of children to passive smoking in their homes
increases the risk of adult lung cancer (Lee
et al. 2000; Vineis et al. 2005), an earlier meta-
analysis estimated the relative risk to be 0.91
(95% CI, 0.8–1.05) (Boffetta et al. 2000).
Even if passive smoking does increase the risk
of adult lung cancer, such exposure occurs
throughout Chile. Finally, occupational expo-
sures to arsenic, such as in the mining and
reﬁning of copper, could contribute to COPD
and lung cancer mortality, but these occupa-
tional exposures mainly involve men, and our
study found similar increases in mortality in
both men and women.
In conclusion, we have demonstrated
pronounced increases in mortality from lung
cancer and bronchiectasis in persons with
probable exposure to high concentrations of
arsenic in drinking water in utero and early
childhood. These findings are important in
that they provide some of the ﬁrst human evi-
dence of effects from environmental exposures
to toxic chemicals in utero and early childhood
resulting in disease in adults. A marked
increase in mortality in young adults is also of
public health importance and should be taken
into consideration in setting arsenic drinking
water standards.
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